Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,773 across all filing types
Latest filing 2022-12-01 Governance Information
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Declaration of Compliance with the German Corporate Governance Code for the year 2022
Governance Information Classification · 1% confidence The document is explicitly titled 'Declaration of Compliance with the German Corporate Governance Code for the year 2022'. It details compliance status regarding the German Corporate Governance Code, mentions the Management Board and Supervisory Board, and cites Section 161 of the German Stock Corporation Act (AktG). This content directly relates to the company's internal rules, board structure, and governance practices, matching the definition for Governance Information (CGR). It is not an Annual Report (10-K), an Audit Report (AR), or a general Regulatory Filing (RNS).
2022-12-01 English
Entsprechenserklärung zum Deutschen Corporate Governance Kodex für das Jahr 2022
Governance Information Classification · 1% confidence The document title is "Entsprechenserklärung zum Deutschen Corporate Governance Kodex für das Jahr 2022" (Declaration of Conformity with the German Corporate Governance Code for the Year 2022). The text explicitly discusses adherence to the principles, recommendations, and suggestions of the German Corporate Governance Code (Kodex) as required by § 161 Aktiengesetz (AktG). This type of declaration detailing internal rules, board structure, and governance practices directly aligns with the definition of Governance Information (CGR). The document is short and contains the declaration itself, not an announcement of a larger report.
2022-12-01 German
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Notification of Major Holdings' under German securities law (WpHG). It reports changes in voting rights percentages held by T. Rowe Price Group, Inc. This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification category.
2022-11-15 English
Präsentation Q3 2022
Investor Presentation Classification · 1% confidence The document is a detailed investor presentation for Evotec SE covering the 9-month (9M) 2022 financial performance, operational highlights, and strategic outlook. It contains financial tables, segment information, and management commentary. It is clearly an investor-facing presentation rather than a formal regulatory filing or a standalone report publication announcement. FY 2022
2022-11-11 English
Evotec SE reports results for the first nine months 2022 and provides corporate update
Earnings Release Classification · 1% confidence The document explicitly states it reports 'results for the first nine months 2022' and provides detailed financial highlights, including Group revenues, Adjusted EBITDA, and segment information for the 9M 2022 period compared to 9M 2021. This content structure, focusing on comprehensive financial performance for a period shorter than a full year (nine months), aligns perfectly with the definition of an Interim/Quarterly Report. The presence of a conference call announcement further supports this being a primary results disclosure, not just a brief announcement (RPA/ER). Therefore, the classification is Interim / Quarterly Report (IR). 9M 2022
2022-11-09 English
Q3 statement / Q3 financial report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM STATEMENT 9M 2022' and contains detailed financial statements, segment information, and management's analysis of the company's performance for the first nine months of the fiscal year. It provides substantive financial data, including income statements and operational highlights, which distinguishes it from a mere announcement or a short summary. Therefore, it is classified as an Interim/Quarterly Report. 9M 2022
2022-11-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.